The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Evidence for a membrane defect in Alzheimer disease brain.
Open accessAbstract
To determine whether neurodegeneration in Alzheimer disease brain is associated with degradation of structural cell membrane molecules, we measured tissue levels of the major membrane phospholipids and their metabolites in three cortical areas from postmortem brains of Alzheimer disease patients and matched controls. Among phospholipids, there was a significant (P less than 0.05) decrease in phosphatidylcholine and phosphatidylethanolamine. There were significant (P less than 0.05) decreases in the initial phospholipid precursors choline and ethanolamine and increases in the phospholipid deacylation product glycerophosphocholine. The ratios of glycerophosphocholine to choline and glycerophosphoethanolamine to ethanolamine were significantly increased in all examined Alzheimer disease brain regions. The activity of the glycerophosphocholine-degrading enzyme glycerophosphocholine choline-phosphodiesterase was normal in Alzheimer disease brain. There was a near stoichiometric relationship between the decrease in phospholipids and the increase of phospholipid catabolites. These data are consistent with increased membrane phospholipid degradation in Alzheimer disease brain. Similar phospholipid abnormalities were not detected in brains of patients with Huntington disease, Parkinson disease, or Down syndrome. We conclude that the phospholipid abnormalities described here are not an epiphenomenon of neurodegeneration and that they may be specific for the pathomechanism of Alzheimer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
A simple, rapid, and sensitive DNA assay procedure
Labarca, C., & Paigen, K. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90165-7 · Cited by 4,901
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
THE FUNCTION OF CYTIDINE COENZYMES IN THE BIOSYNTHESIS OF PHOSPHOLIPIDES
Kennedy, E. P., & Weiss, S. B. (1956) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50785-2 · Cited by 1,810
Cleavage of Amyloid β Peptide During Constitutive Processing of Its Precursor
Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., & Ward, P. J. (1990) · Science · doi:10.1126/science.2111583 · Cited by 1,410
Evidence that β-Amyloid Protein in Alzheimer's Disease Is Not Derived by Normal Processing
Sisodia, S. S., Koo, E. H., Beyreuther, K., Unterbeck, A., & Price, D. L. (1990) · Science · doi:10.1126/science.1691865 · Cited by 893
Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease
Rumble, B., Retallack, R., Hilbich, C., Simms, G., Multhaup, G., Martins, R., Hockey, A., Montgomery, P., Beyreuther, K., & Masters, C. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906013202203 · Cited by 653
Choline and Cholinergic Neurons
Blusztajn, J. K., & Wurtman, R. J. (1983) · Science · doi:10.1126/science.6867732 · Cited by 443
Self-citationAcetylcholine and Choline in Neuronal Tissue Measured by HPLC with Electrochemical Detection
Potter, P. E., Meek, J. L., & Neff, N. H. (1983) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1983.tb13668.x · Cited by 409
Cited by
Oxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Oxidative stress and Alzheimer disease
Christen, Y. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.621s · Cited by 1,158
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Butterfield, D. A., & Lauderback, C. M. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00794-3 · Cited by 1,001
Complement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Chemical Basis of Reactive Oxygen Species Reactivity and Involvement in Neurodegenerative Diseases
Collin, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102407 · Cited by 816
Oxidative Alterations in Alzheimer's Disease
Markesbery, W. R., & Carney, J. M. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00215.x · Cited by 784
Choline: Critical Role During Fetal Development and Dietary Requirements in Adults
Zeisel, S. H. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111156 · Cited by 741
“Abnormal phospholipid metabolism in Alzheimer's disease (96) results in reduced levels in brain (at autopsy) of phosphatidylcholine, phosphatidylethanolamine, choline, and ethanolamine and increased levels of glycerophosphocholine and glycerophosphoethanolamine.”
Review: Alzheimer's Amyloid β-Peptide-Associated Free Radical Oxidative Stress and Neurotoxicity
Varadarajan, S., Yatin, S., Aksenova, M., & Butterfield, D. A. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4274 · Cited by 735
Auld, D. S., Kornecook, T. J., Bastianetto, S., & Quirion, R. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00079-5 · Cited by 666
The redox chemistry of the Alzheimer's disease amyloid β peptide
Smith, D. G., Cappai, R., & Barnham, K. J. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.02.002 · Cited by 608
Poirier, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., & Gilfix, B. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.12260 · Cited by 595
Choline and betaine in health and disease
Ueland, P. M. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9088-4 · Cited by 576
Farooqui, A. A., Horrocks, L. A., & Farooqui, T. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00128-6 · Cited by 555
Castellani, R. J., Rolston, R. K., & Smith, M. A. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2010.06.001 · Cited by 519
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
Oxidative stress: Free radical production in neural degeneration
Götz, M. E., Künig, G., Riederer, P., & Youdim, M. B. H. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90055-8 · Cited by 482
Amyloid toxicity in Alzheimer’s disease
Reiss, A. B., Arain, H. A., Stecker, M. M., Siegart, N. M., & Kasselman, L. J. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0063 · Cited by 447
Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches
Behl, C. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00055-0 · Cited by 445
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Regional Membrane Phospholipid Alterations in Alzheimer's Disease
Prasad, M. R., Lovell, M. A., Yatin, M., Dhillon, H., & Markesbery, W. R. (1998) · Neurochemical Research · doi:10.1023/a:1022457605436 · Cited by 439
Glucose metabolism and insulin receptor signal transduction in Alzheimer disease
Hoyer, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.049 · Cited by 434
Elevated 4-Hydroxynonenal in Ventricular Fluid in Alzheimer’s Disease
Lovell, M. A., Ehmann, W. D., Mattson, M. P., & Markesbery, W. R. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00108-5 · Cited by 412
A detergent-insoluble membrance compartment contains Aβ in vivo
Lee, S.-J., Liyanage, U., Bickel, P. E., Xia, W., Lansbury, P. T., & Kosik, K. S. (1998) · Nature Medicine · doi:10.1038/nm0698-730 · Cited by 395
Are reactive oxygen species involved in Alzheimer's disease?
Benzi, G. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00066-n · Cited by 365
Svennerholm, L., & Gottfries, C. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62031039.x · Cited by 330
Efficacy of Souvenaid in Mild Alzheimer's Disease: Results from a Randomized, Controlled Trial
Scheltens, P., Twisk, J. W. R., Blesa, R., Scarpini, E., von Arnim, C. A. F., Bongers, A., Harrison, J., Swinkels, S. H. N., Stam, C. J., de Waal, H., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121189 · Cited by 306
Self-citationPettegrew, J. W., Levine, J., & McClure, R. J. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000805 · Cited by 304
Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids
Klein, J. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070051 · Cited by 303
Nutritional modulation of cognitive function and mental health
Parletta, N., Milte, C. M., & Meyer, B. J. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.01.002 · Cited by 302
Neuroprotective Actions of Dietary Choline
Blusztajn, J., Slack, B., & Mellott, T. (2017) · Nutrients · doi:10.3390/nu9080815 · Cited by 293
“Evidence that phospholipid metabolism is abnormal in AD originated with postmortem brain sample studies dating to the 1980s and 1990s [165–168] which showed reduced levels of PC and phosphatidylethanolamine (PE) and increased levels of their metabolites, glycerophosphocholine and glycerophosphoethanolamine, respective…”
ResultSelf-citationThe role of glucose transporters in brain disease: Diabetes and Alzheimer’s disease
Shah, K., DeSilva, S., & Abbruscato, T. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012629 · Cited by 288
Brain Membrane Phospholipid Alterations in Alzheimer's Disease
Pettegrew, J. W., Panchalingam, K., Hamilton, R. L., & McClure, R. J. (2001) · Neurochemical Research · doi:10.1023/a:1011603916962 · Cited by 292
Bottiglieri, T. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.5.1151s · Cited by 286
Arachidonic acid as a neurotoxic and neurotrophic substance
Katsuki, H., & Okuda, S. (1995) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00016-o · Cited by 280
Sultana, R., Ravagna, A., Mohmmad‐Abdul, H., Calabrese, V., & Butterfield, D. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02899.x · Cited by 276
Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis
Haughey, N. J., Bandaru, V. V. R., Bae, M., & Mattson, M. P. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.003 · Cited by 273
Quantitative proton MR spectroscopic imaging of the human brain
Soher, B. J., van Zijl, P. C. M., Duyn, J. H., & Barker, P. B. (1996) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910350313 · Cited by 271
Direct and Potent Regulation of γ-Secretase by Its Lipid Microenvironment
Osenkowski, P., Ye, W., Wang, R., Wolfe, M. S., & Selkoe, D. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801925200 · Cited by 268
Hoyer, S. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050067 · Cited by 265
Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases
Filippov, V., Song, M. A., Zhang, K., Vinters, H. V., Tung, S., Kirsch, W. M., Yang, J., & Duerksen-Hughes, P. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111202 · Cited by 264
“Since the first report in 1992 of a decrease in the level of total phospholipids in AD brains [14], this observed disturbance in the metabolism of sphingolipids, including ceramide, during AD has led to several attempts to identify the genes and proteins responsible for this dysregulation.”
BackgroundSultana, R., Perluigi, M., & Butterfield, D. A. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.2021 · Cited by 262
Mitochondria-associated ER membranes in Alzheimer disease
Schon, E. A., & Area-Gomez, E. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.07.011 · Cited by 261
Bertrand, P., Poirier, J., Oda, T., Finch, C. E., & Pasinetti, G. M. (1995) · Molecular Brain Research · doi:10.1016/0169-328x(95)00097-c · Cited by 210
Wurtman, R. J., Ulus, I. H., Cansev, M., Watkins, C. J., Wang, L., & Marzloff, G. (2006) · Brain Research · doi:10.1016/j.brainres.2006.03.019 · Cited by 169
Self-citationLipidomics of Alzheimer's disease: current status
Wood, P. L. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt103 · Cited by 167
van Wijk, N., Broersen, L. M., de Wilde, M. C., Hageman, R. J. J., Groenendijk, M., Sijben, J. W. C., & Kamphuis, P. J. G. H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130998 · Cited by 128
Tong, B., Ba, Y., Li, Z., Yang, C., Su, K., Qi, H., Zhang, D., Liu, X., Wu, Y., Chen, Y., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106505 · Cited by 117
Fagan, A. M., Murphy, B. A., Patel, S. N., Kilbridge, J. F., Mobley, W. C., Bu, G., & Holtzman, D. M. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6818 · Cited by 116
APOE alters glucose flux through central carbon pathways in astrocytes
Williams, H. C., Farmer, B. C., Piron, M. A., Walsh, A. E., Bruntz, R. C., Gentry, M. S., Sun, R. C., & Johnson, L. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104742 · Cited by 105
Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice
Krzywkowski, P., Ghribi, O., Gagné, J., Chabot, C., Kar, S., Rochford, J., Massicotte, G., & Poirier, J. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00061-5 · Cited by 74
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
He, S., Xu, Z., & Han, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00803-6 · Cited by 62
Potential genetic markers of sporadic Alzheimerʼs dementia
Retz, W., Thome, J., Durany, N., Harsányi, A., Retz-Junginger, P., Kornhuber, J., Riederer, P., & Rösler, M. (2001) · Psychiatric Genetics · doi:10.1097/00041444-200109000-00002 · Cited by 48
Age as Risk Factor for Sporadic Dementia of the Alzheimer Type?
HOYER, S. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb56833.x · Cited by 38
Changes in lipid metabolism track with the progression of neurofibrillary pathology in tauopathies
Olešová, D., Dobešová, D., Majerová, P., Brumarová, R., Kvasnička, A., Kouřil, Š., Stevens, E., Hanes, J., Fialová, Ľ., Michalicová, A., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03060-4 · Cited by 33
A unifying hypothesis of alzheimer’s disease: III—Risk factors
Heininger, K. (2000) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/(sici)1099-1077(200001)15:1<1::aid-hup153>3.0.co;2-1
Metadata
- Authors
- Nitsch, R. M., Blusztajn, J. K., Pittas, A. G., Slack, B. E., Growdon, J. H., & Wurtman, R. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1992-03
- Volume
- 89
- Issue
- 5
- Pages
- 1671-1675
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1995954863
- Cited by
- 536
- References
- 28
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.